BTK and B-cell chronic lymphocytic leukemia: The non-catalytic functions of BTK might also play an important role for treating B cell malignancies such as chronic lymphocytic leukemia for which BTK inhibitors such as ibrutinib are increasingly prescribed, even in first line now [28].